The diagnostics industry is overdue for disruption, with outdated and inefficient testing methods limiting real-time treatment optimization. This company has developed a revolutionary biosensor platform that enables rapid, scalable, and highly specific drug and biomarker detection, dramatically improving diagnostics for metabolic health, chronic pain, and impairment testing.
Unlike traditional diagnostics that rely on costly, slow, and often imprecise methods, this company’s yeast-based receptor-binding assays use AI-enhanced biosensors to detect active drug metabolites and physiological responses in real-time—transforming how treatments are prescribed, optimized, and monitored.
With strong intellectual property, partnerships with leading research institutions, and a clear path to commercialization across multiple billion-dollar markets, the company is currently raising funds to accelerate regulatory approvals and market entry. This is a rare opportunity to invest early in a company positioned to redefine diagnostic precision across multiple industries.
View the deck through the link below. Some unique identifiers have been removed. For access to detailed materials, please reach to us or your point of contact, as full decks are only shared upon request to maintain confidentiality and exclusivity.
View Pitch Deck